InSilico Medicine Cayman TopCo (“Insilico Medicine” or “the Company”) has been chosen by Hang Seng Indexes Company Limited to become a constituent stock of the Hang Seng Composite Index (“HSCI”), effective March 9, 2026. According to the announcement, the Company’s shares are expected to meet the inclusion criteria for trading via both the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect upon this addition.

The Company’s board of directors stated that inclusion in the HSCI highlights recognition from the international capital market regarding Insilico Medicine’s industry position and business value. The board further noted that this development could improve stock liquidity, diversify its shareholder base, and support the Company’s long-term development.

Insilico Medicine is a global biotechnology enterprise that leverages artificial intelligence and automation technologies to enhance drug discovery and drive progress within the life sciences. It was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK, focusing on areas such as fibrosis, oncology, immunology, pain, and metabolic disorders, alongside broader applications of its Pharma.AI platform.